Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CXCR2-modified CD70 CAR T cells

A preparation composed of ex-vivo expanded CXC chemokine receptor 2 (CXCR2) modified patient-derived activated CD70 (CD27 ligand; tumor necrosis factor superfamily member 7; TNFSF7) chimeric antigen receptor (CAR) (8R-70CAR) T cells, with potential immunostimulating and antineoplastic activities. Upon admi nistration of the autologous CXCR2-modified CD70 CAR Tcells, the anti-CD70-CARs on the T cell surfaces target and bind to the CD70 antigen on tumor cell surfaces. This induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against CD70-expressing tumor cells. CD70, a cytokine belonging to the tumor necrosis factor superfamily (TNFSF) and the ligand for the costimulatory receptor CD27, is expressed on the surfaces of various types of cancer cells; its overexpression may play an important role in the evasion of immune surveillance. CXCR2, a transmembrane protein also known as interleukin (IL)-8 receptor B (IL-8RB), plays a key role in inflammation and cancer progression. Certain CXCR2 ligands, such as CXCL1 and CXCL8 (IL-8), are expressed by tumor cells. CXCR2-modified CARs enhance intratumoral T-cell trafficking toward tumor cells and promotes persistence of T cells. This may enhance the T-cell-mediated immune response against the CD70-expressing tumor cells.
Synonym:autologous 8R-70CAR T cells
autologous IL-8RB-modified CD70-CAR T cells
Search NCI's Drug Dictionary